This approach allowed the authors to examine the detailed impact of recurrent KMT2D and EZH2 mutations on the histone modification landscape and its cell-cell variability, both in patient-derived xenografts and isogenic DLBCL cell lines. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.